KZIA — KAZIA THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1075880 ·
Australia
Last close
$5.31
Market Cap
$60.68M
52W High
$17.40
52W Low
$4.86
ADV30
265,643
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 71,112,533 | 69,459,980 | 24,645,494 |
| Jun 2025 | — | — | — | — | 6,061,000 | 4,345,000 | 14,362,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,609,696
Inventory
—
Receivables
$307,852
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,898,631
EBITDA
$-17,840,660
Free Cash Flow
$1,099,920
Enterprise Value
$57,488,568
Total Cash
$69,459,984
Total Debt
$98,807
Shares Out
11,426,899
Trailing EPS
$-7.68
Book Value
$2.94
ROE
-106.9%
ROA
-25.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 42,000 | -14,217,000 | -20,702,000 | 6,061,000 | 14,362,000 | -8,301,000 | -13,278,000 |
| Jun 2024 | 2,308,000 | -28,462,000 | -26,778,000 | 21,585,000 | 31,602,000 | -10,017,000 | -9,581,000 |
| Jun 2023 | 0 | -24,146,000 | -20,465,000 | 28,084,000 | 16,034,000 | 12,050,000 | -15,156,000 |
| Jun 2022 | 0 | -25,399,000 | -25,014,000 | 35,889,000 | 17,614,000 | 18,275,000 | -22,762,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $5.49 · call volume: 42 · put volume: 40
Expected Move to 2027-05-21:
±$6.00
(109.29%) —
implied range
$-0.51 –
$11.49
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | $60.70M | $1.82 | — |
| LFVN | Lifevantage Corp | $60.62M | $4.78 | — |
| ACRV | Acrivon Therapeutics, Inc. | $61.28M | $1.43 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $62.03M | $3.01 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $57.91M | $0.55 | — |
News headlines (Yahoo Finance, 1h cache)
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
2026-11-12 12:00 · Yahoo
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
2026-11-05 12:00 · Yahoo
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
2026-11-02 12:00 · Yahoo
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-10-29 11:00 · Yahoo
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
2026-09-22 11:30 · Yahoo
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
2026-09-09 11:30 · Yahoo
Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate
2026-09-19 22:15 · Yahoo
Reddit downgraded, Rivian upgraded: Wall Street's top analyst calls
2026-10-30 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.